Joint Statement on Potential Cardiovascular Risks Associated with Rosiglitazone
July 12, 2010--Collectively, AACE, ADA, and the Society continue to carefully review the information on rosiglitazone available in the public domain and await further information from the Food and Drug Administration (FDA)...

Statement to Providers on Study Findings Related to Treatment of Hypertension in Patients with Diabetes
On March 14, three studies presented at an American College of Cardiology meeting raised questions about whether normalization of blood pressure in hypertensive patients with diabetes or those with...

Alert: FDA Guidance on Liraglutide
The U.S. Food and Drug Administration (FDA) recently approved the once daily injectable drug liraglutide (Victoza) for use in the United States. The medication, used as an adjunct to diet and exercise...

Alert: President’s Budget Provides 3% Increase to NIH
The President unveiled his fiscal year (FY) 2011 budget on February 1, and as outlined in his State of the Union address, domestic discretionary spending was held to FY 2010 levels.  While many programs were cut under the President’s...

Alert: Society Recommends Against Altering Blood Glucose Control Goals
Several studies in the last two decades have shown that improved glycemic control reduces complications in Type 1 and Type 2 diabetes both during the period of intensive treatment and for years thereafter (the “legacy” effect)...